KING OF PRUSSIA, Pa., July 23, 2018 /PRNewswire/ -- Imalogix, a leader in artificial intelligence process and workflow solutions, today announced the availability of the latest evolution to its platform for Diagnostic Imaging, Interventional Radiology, Cardiology, and Surgery.
The Imalogix Platform provides a comprehensive infrastructure to enable healthcare organizations to better understand and manage process, quality and safety related to diagnostic imaging services, interventional procedures and meet evolving regulatory standards with ease. The platform currently supports all requirements from The Leapfrog Group and the Joint Commission (TJC), including the recently announced radiation standards for fluoroscopy services set to take effect in January of 2019.
Imalogix CEO and co-founder, John Heil said, "Without a process to automate the calculations required for interventional procedures, it would be virtually impossible to meet the upcoming requirements from the Joint Commission. Our platform makes this process simple, while providing insights to departments to understand how procedures are being delivered to enhance patient safety."
The Imalogix Platform enables departments utilizing fluoroscopy procedures to manage and enhance the safety and quality of exams through a comprehensive view of peak skin dose (PSD) across their entire patient population. Without an automated solution in place, this calculation is primarily utilized retrospectively to review and determine overexposure of exams due to the complex nature and length of time required to manually calculate PSD. The impending regulations surrounding fluoroscopy from TJC state that this calculation is required for every fluoroscopy exam.
"Within minutes of getting up and running with Imalogix, I was able to determine the peak skin dose for an extremely complex procedure. This would have taken days to calculate previously, but now it is automatic, said Thomas Griglock, PhD, DABR Chief Diagnostic Imaging Physicist, Oregon Health & Science University. This feature alone has equated to a significant time and resource saving. With the capabilities that Imalogix provides, we are focusing on optimizing radiation practices to continuously improve the quality and safety of care for our patients."
Now with the ability to instantly calculate PSD by patient and classify this information by exam type, organizations can determine realistic radiation dose estimates for different procedure types to better protect patients and physicians. The Imalogix Platform also automatically alerts designated staff for procedures that emit over 5 Gray (Gy) and tracks patient cumulative dose to help ensure all sentential events (15 Gy) are either avoided or flagged for immediate review and patient follow-up.
Charles Dodge, PhD, DABR, Director of Radiation Safety and Imaging Physics, Houston Methodist said, "Imalogix's alerting and auto-notification features help me keep up with regulatory and accreditation compliance. The amount of detail Imalogix provides, has freed my time to focus on specific individuals and protocols where additional optimization is required, helping me to reduce patient doses and improved image quality."
To learn more, visit www.imalogix.com or visit Imalogix in person at AAPM booth 201 or AHRA booth 1025.
About Imalogix:
Imalogix is a leader in artificial intelligence and workflow solutions that support healthcare providers to better understand and mange process, quality and safety relation to diagnostic imaging services, interventional procedures, and meet evolving regulatory standards with ease. Imalogix has been exclusively endorsed by the American Hospital Association. For more information, visit www.imalogix.com.
SOURCE Imalogix